Tenax Therapeutics
TENX
12 hedge funds and large institutions have $1.46M invested in Tenax Therapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
20% more funds holding
Funds holding: 10 → 12 (+2)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
7% less capital invested
Capital invested by funds: $1.56M → $1.46M (-$105K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$64.4K |
| 2 |
VF
Virtu Financial
New York
|
+$22.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.7K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$12.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $719K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $491K | +$64.4K | +31 | +14% |
|
|
FWP
3
FAS Wealth Partners
Leawood,
Kansas
| $70K | – | – | – |
|
4
Bank of New York Mellon
New York
| $43K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $39K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $29K | +$18.7K | +9 | +150% |
|
|
VF
7
Virtu Financial
New York
| $21K | +$22.9K | +11 | New |
|
8
Vanguard Group
Malvern,
Pennsylvania
| $15K | – | – | – |
|
|
ARTA
9
A.R.T. Advisors
New York
| $12K | +$12.5K | +6 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| $11K | +$10.4K | +5 | +500% |
|
|
LTFS
11
Ladenburg Thalmann Financial Services
Miami,
Florida
| $6K | +$6.24K | +3 | New |
|
|
AG
12
Advisor Group
Phoenix,
Arizona
| $4K | – | – | – |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$30K | -13 | Closed |
|
TENX Hedge Fund Activity: Q3 2019 in Review
12 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q3 2019, worth a combined $1.46M — down 6.7% from $1.56M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TENX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $64.4K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $30K sold.
- 12 institutional investors held Tenax Therapeutics (TENX) as of Q3 2019, up from 10 in Q2 2019.
- Funds reported $1.46M of Tenax Therapeutics stock for Q3 2019, down 6.7% quarter-over-quarter.
- 3 funds opened new Tenax Therapeutics positions in Q3 2019 and 1 closed out, a net change of +2 holders.
- The largest Tenax Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $64.4K added.
- The largest Tenax Therapeutics seller in Q3 2019 was Susquehanna International Group, an estimated $30K sold.
Based on aggregated 13F filings for Q3 2019.